- Home
- KNSA vs IDYA Comparison
KNSA vs IDYA Comparison
Compare KNSA & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- IDYA
- Stock Information
- Founded
- KNSA 2015
- IDYA 2015
- Country
- KNSA United Kingdom
- IDYA United States
- Employees
- KNSA N/A
- IDYA N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- KNSA Health Care
- IDYA Health Care
- Exchange
- KNSA Nasdaq
- IDYA Nasdaq
- Market Cap
- KNSA 1.9B
- IDYA 2.3B
- IPO Year
- KNSA 2018
- IDYA 2019
- Fundamental
- Price
- KNSA $35.71
- IDYA $27.16
- Analyst Decision
- KNSA Strong Buy
- IDYA Buy
- Analyst Count
- KNSA 6
- IDYA 14
- Target Price
- KNSA $40.83
- IDYA $49.17
- AVG Volume (30 Days)
- KNSA 439.9K
- IDYA 953.6K
- Earning Date
- KNSA 10-28-2025
- IDYA 11-03-2025
- Dividend Yield
- KNSA N/A
- IDYA N/A
- EPS Growth
- KNSA N/A
- IDYA N/A
- EPS
- KNSA 0.07
- IDYA N/A
- Revenue
- KNSA $529,332,000.00
- IDYA $7,000,000.00
- Revenue This Year
- KNSA $37.21
- IDYA $62.30
- Revenue Next Year
- KNSA $11.99
- IDYA $285.58
- P/E Ratio
- KNSA $539.78
- IDYA N/A
- Revenue Growth
- KNSA 56.18
- IDYA N/A
- 52 Week Low
- KNSA $17.82
- IDYA $13.45
- 52 Week High
- KNSA $35.82
- IDYA $39.30
- Technical
- Relative Strength Index (RSI)
- KNSA 72.49
- IDYA 70.30
- Support Level
- KNSA $33.25
- IDYA $24.04
- Resistance Level
- KNSA $34.16
- IDYA $25.39
- Average True Range (ATR)
- KNSA 0.83
- IDYA 1.05
- MACD
- KNSA 0.07
- IDYA 0.16
- Stochastic Oscillator
- KNSA 95.59
- IDYA 99.45
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.